GlassScriptPhysician profile
John Vincent Knaus
NPI 1326023714
$3,701.06
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,077 · 2020: $378 · 2021: $246.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $2,227.60 | 2019 | |
| Daiichi Sankyo INC. | $315.66 | 2020-2021 | |
| Clovis Oncology, INC. | $224.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $192.43 | 2019-2021 | |
| Amgen INC. | $132.29 | 2019 | |
| Abbvie INC. | $120.09 | 2019-2021 | |
| Therapeuticsmd, INC. | $98.97 | 2019-2021 | |
| Coopersurgical, INC. | $67.26 | 2019 | |
| Vertical Pharmaceuticals, LLC | $58.18 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $46.54 | 2019-2021 | |
| Pfizer INC. | $44.25 | 2021 | |
| Hologic Sales and Service, LLC | $41.36 | 2019 | |
| Dysis Medical, INC. | $33.85 | 2019-2020 | |
| Astellas Pharma US INC | $23.05 | 2020 | |
| Eisai INC. | $22.50 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $21.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $16.78 | 2019 | |
| Focal Therapeutics, INC. | $15.05 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Knaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.